Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07038941 | Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia | PHASE1 | COMPLETED | 44 | — | — | Mar 19, 2024 | Jun 2, 2024 | Jun 26, 2025 | 1 | China |
Incidence and severity of adverse events, vital signs, physical examination, laboratory tests, electrocardiogram, etc.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | 5% minoxidil and 0.025% finasteride, 1 gram Only once on Day 1 |
| Arm 2 | EXPERIMENTAL | 5% minoxidil and 0.05% finasteride, 1 gram Once a day from Day 1 to Day 7 |
| Arm 3 | EXPERIMENTAL | 5% minoxidil and 0.075% finasteride, 1 gram Once a day from Day 1 to Day 7 |
| Arm 4 | EXPERIMENTAL | 5% minoxidil and 0.1% finasteride, 1 gram Once a day from Day 1 to Day 7 |
| Arm 5 | EXPERIMENTAL | 5% minoxidil and 0.1% finasteride, 1 gram Once a day on Day 1, twice daily on Day 2 to Day 6, once a day on Day 7 |
| Arm 6 | PLACEBO_COMPARATOR | Placebo foam, 1 gram Once a day from Day 1 to Day 7 |
| Arm 7 | PLACEBO_COMPARATOR | Placebo foam, 1 gram Once a day on Day 1, twice daily on Day 2 to Day 6, once a day on Day 7 |
| Name | Type | Description |
|---|---|---|
| CG2001 | DRUG | combination of minoxidil and finasteride |
| Placebo foam | DRUG | Placebo foam |
Inclusion Criteria: Participants must meet all of the following criteria to be included: 1. Voluntarily sign the informed consent form approved by the ethics committee before any research procedures begin; 2. Be able to understand and comply with the requirements of the protocol, and agree to coop...